Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof

Patent metadata

Field	Value
Publication number	US-2016015773-A1
Application number	US-201514699620-A
Country	US
Kind code	A1
Filing date	Apr 29, 2015
Priority date	Apr 8, 2010
Publication date	Jan 21, 2016
Grant date	—

Abstract

The present invention relates to polypeptides fragments derived from the protein TLT-1 and their uses for the treatment of inflammatory conditions and more particularly for the treatment of sepsis.

First claim

1 - 9 . (canceled)

10 . A method for treating an inflammatory condition, comprising administering to a subject in need thereof a polypeptide of 6 to 20 amino acids comprising at least 6 consecutive amino acids selected from the amino acid sequence SEQ ID NO 1 or a function-conservative variant thereof.

11 . The method according to claim 10 , wherein said polypeptide comprises a 6 consecutive amino acid sequence from the amino acid sequence SEQ ID NO 4 or a function-conservative variant thereof.

12 . The method according to claim 10 , wherein said polypeptide comprises a 6 consecutive amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO 7 or SEQ ID NO 8.

13 . The method according to claim 10 , wherein said polypeptide comprises an amino acid sequence as set forth in SEQ ID NO 9.

14 . The method according to claim 10 , wherein said polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 4.

15 . A method according to claim 10 , wherein the inflammatory condition is selected from the group consisting of allergies, asthma, cancer, inflammatory arthritis, inflammatory bowel disease, acute respiratory distress syndrome (ARDS), pancreatitis, pneumonia, systemic inflammatory response syndrome (SIRS), severe acute respiratory syndrome (SARS), sepsis, severe sepsis, septic shock, endotoxemia, ischemia and reperfusion syndromes and hemorrhagic shock.

16 . A method according to claim 10 , wherein the inflammatory condition is selected from the group consisting of acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), severe acute respiratory syndrome (SARS), sepsis, severe sepsis, septic shock and endotoxemia

17 . A method according to claim 10 , wherein the inflammatory condition is sepsis.

Assignees

• Gibot Sebastien
• Derive Marc
• Inst Nat Sante Rech Med
• Univ Lorraine

Inventors

• Gibot Sebastien
• Derive Marc

Classifications

• A61K38/08

  Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K38/10 Primary

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P31/04

  Antibacterial agents · CPC title